Skip to content

Single-Dose versus Long-Term Antibiotic Prophylaxis for Breast Reconstruction with Tissue Expanders

Infection Rates in Patients Receiving Single-Dose or Long-Term Antibiotic Prophylaxis for Breast Reconstruction with Tissue Expanders

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12611000701921
Enrollment
80
Registered
2011-07-08
Start date
2008-10-26
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This small study did not reveal a significant difference between single-dose versus long-term antibiotic prophylaxis, although all infections occurred in patients in the single-dose antibiotic group. Further studies are needed to determine whether the common practice of prolonged antibiotic use after immediate reconstruction with tissue expanders is beneficial.

Interventions

Arm 1: Single Perioperative Antibiotic Dose. Patients received 1-2 grams of cefazolin intravenously within 30 minutes prior to surgery, based on the participant’s weight (1 gram for less than 100 kg & 2 grams for greater than 100 kg). Arm 2: Prolonged Antibiotic Dose. Patients also received 1-2 grams of cefazolin intravenously within 30 minutes prior to surgery, based on the participant’s weight (1 gram for less than 100 kg & 2 grams for greater than 100 kg). After surgery patients received

Arm 1: Single Perioperative Antibiotic Dose. Patients received 1-2 grams of cefazolin intravenously within 30 minutes prior to surgery, based on the participant’s weight (1 gram for less than 100 kg & 2 grams for greater than 100 kg). Arm 2: Prolonged Antibiotic Dose. Patients also received 1-2 grams of cefazolin intravenously within 30 minutes prior to surgery, based on the participant’s weight (1 gram for less than 100 kg & 2 grams for greater than 100 kg). After surgery patients received an additional 24 hours of intravenous dosing of cefazolin and then seven days of cephalexin 500 mg by mouth 3-4 times per day as directed.

Sponsors

The University of Kansas School of Medicine - Wichita
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age greater than or equal to 18 2. Female 3. Patients undergoing mastectomy with immediate breast reconstruction with tissue expanders 4. Patients who sign informed consent 5. Patients who do not meet any of the exclusion criteria

Exclusion criteria

1. Age less than or equal to 17 2. Patients with ongoing systemic infection at the time of surgery 3. Patients who are pregnant or planning to become pregnant 4. Patients allergic to cephalosporins

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026